UC San Francisco (Video)

UC San Francisco (Video)

By UCTV
Download on the App Store

UC San Francisco (Video) episodes

  • Prostate Cancer: PSA Recurrence and Risk Assessment
    Dr. Steven Seyedin presents an overview of PSA recurrence and risk factors for assessment. A PSA test is a blood test used to detect prostate-specific antigen (PSA) levels in the blood, which can be elevated in cases of prostate cancer and is a common screening tool. He explains how PET, CT, and MRI work, highlighting the precision of PSA PET in detecting cancer spread by targeting PSA proteins on tumor cells. This imaging method combines PET and CT to reveal metastatic disease with greater accuracy than traditional scans. Seyedin addresses the strengths of different imaging agents, emphasizing that access, not brand, is key. He also cautions against false positives, especially in bone lesions, which can mislead diagnosis. By improving staging accuracy, PSA PET supports better treatment planning and outcomes. Ongoing studies explore its use earlier in diagnosis, potentially replacing biopsy or MRI in select cases. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40805]
    14 min
  • Prostate Cancer: Optimizing Bone Health
    Prostate cancer and its treatments can significantly impact bone health, increasing the risk of fractures and weakening the immune system. Dr. Terence Friedlander explains how hormone therapy, radiation, and chemotherapy contribute to bone loss and highlights the importance of regular monitoring. He reviews the role of bone-building cells and the effects of osteopenia and osteoporosis, conditions that become more common with age and can be worsened by cancer therapies. Friedlander outlines tools like the Dexa scan and FRAX calculator to assess bone density and fracture risk, and discusses prevention strategies, including adequate calcium and vitamin D intake, weight-bearing exercise, and the use of medications like bisphosphonates and denosumab. He emphasizes proactive bone care for men with prostate cancer to help reduce complications and improve outcomes. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40812]
    11 min
  • Metastatic Hormone-Sensitive Prostate Cancer
    Dr. Kelly Fitzgerald explains current standards of care for metastatic hormone-sensitive prostate cancer, focusing on treatment strategies shaped by both clinical trial data and emerging imaging technologies. She defines key terms such as poly- and oligometastatic disease and outlines how newer imaging methods like PSMA PET scans are reshaping diagnosis. She describes the shift from traditional androgen deprivation therapy (ADT) to intensified ADT, where additional agents—such as chemotherapy or novel hormone therapies—are shown to improve survival. Fitzgerald also reviews ongoing questions around triplet therapy and the potential benefits of local treatments like radiation. She highlights the importance of patient-specific factors and the evolving definitions that influence treatment decisions in this complex disease landscape. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40809]
    10 min
  • Diagnosis of Prostate Cancer
    UCSF’s Dr. Cornelia Ding demystifies the prostate cancer pathology report and explains how to read and understand it. The report contains five key sections: patient information, diagnosis and comments, gross description, and any addendums or amendments. It serves multiple purposes—as a medical, legal, and clinical communication tool—and often contains technical language not written for patients. Dr. Ding walks through important terminology such as Gleason score, Grade Groups, and specific diagnostic patterns like intraductal carcinoma, emphasizing how each affects risk assessment and treatment planning. Patients are encouraged to focus on the diagnosis and comment sections and to discuss any unclear details with their doctors. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40797]
    15 min
  • Prostatectomy for Localized Prostate Cancer
    Dr. Samuel Washington presents an in-depth overview of prostatectomy, a surgical option for treating prostate cancer confined to the prostate gland. He explains how robotic-assisted laparoscopic surgery allows for precise removal of the prostate and seminal vesicles while minimizing recovery time and hospital stay. Washington discusses the importance of imaging, biopsy results, and patient risk levels in guiding decisions about lymph node removal and nerve-sparing techniques. He emphasizes realistic expectations around recovery, including urinary incontinence and erectile dysfunction, and outlines strategies for managing these outcomes, such as rehabilitation programs and medication. He also addresses the anatomical changes caused by surgery and the impact on fertility and sexual function. Emerging technologies aim to further improve surgical precision and cancer removal. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40802]
    13 min
  • Prostate Cancer Overview
    Prostate cancer remains the most commonly diagnosed cancer and second leading cause of cancer death among men in the U.S., with evolving screening and treatment practices reshaping care in 2025. UCSF's Dr. Matthew Cooperberg highlights a shift away from overdiagnosis and overtreatment of low-risk cancers, focusing instead on identifying aggressive disease through tools like MRI and advanced biomarker tests. A new “smarter screening” model now guides primary care, recommending long testing intervals for men with low PSA levels. While active surveillance has increased nationally, significant variation in care remains, and racial disparities—especially for Black men—persist. Patients are encouraged to take time in making treatment decisions, as prostate cancer often progresses slowly and allows for thoughtful, personalized care. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40796]
    13 min
  • Prostate Cancer: The ABCs of Androgen Deprivation Therapy
    In this presentation, UCSF’s Dr. Eric Small explains the role of androgen deprivation therapy (ADT) in prostate cancer treatment across various stages of the disease. He discusses how prostate cancer cells rely on testosterone to grow and how medications can effectively reduce testosterone levels by targeting hormone signals or blocking production. Dr. Small outlines the different forms of ADT—injectables, implants, and pills—and reviews their pros, cons, and side effect profiles, including cardiovascular considerations. He also describes how combining ADT with newer androgen signaling inhibitors has improved survival outcomes in patients with metastatic or recurrent disease. The talk emphasizes the importance of balancing treatment benefits with side effects and highlights the role of shared decision-making in choosing the right approach. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40799]
    21 min

About UC San Francisco (Video)

From the publisher's feed

Programs from the University of California, San Francisco.

More shows like UC San Francisco (Video)

Aging and Senior Health (Audio) by UCTV

Aging and Senior Health (Audio)

21 Listeners

Aging and Senior Health (Video) by UCTV

Aging and Senior Health (Video)

4 Listeners

Physics (Audio) by UCTV

Physics (Audio)

2 Listeners

Evolution by UCTV

Evolution

17 Listeners

Communication and Media Studies (Audio) by UCTV

Communication and Media Studies (Audio)

0 Listeners

Cardiology (Audio) by UCTV

Cardiology (Audio)

17 Listeners

Holocaust (Audio) by UCTV

Holocaust (Audio)

47 Listeners

CARTA - Anthropogeny (Audio) by UCTV

CARTA - Anthropogeny (Audio)

7 Listeners

Robert Reich by UCTV

Robert Reich

7 Listeners

Robert Reich by UCTV

Robert Reich

34 Listeners